N. Dirks and B. Meibohm, Population Pharmacokinetics of Therapeutic Monoclonal Antibodies, Clinical Pharmacokinetics, vol.27, issue.7, pp.633-59, 2010.
DOI : 10.2165/11535960-000000000-00000

T. Gangadhar, J. Mehnert, and A. Patnaik, Population pharmacokinetic (popPK) model of pembrolizumab (pembo; MK-3475) in patients (pts) treated inKEYNOTE-001 and KEYNOTE-002, J Clin Oncol, vol.33, 2015.

A. Patnaik, S. Kang, and D. Rasco, Phase I study of pembrolizumab (MK-3475

E. Garon, N. Rizvi, and R. Hui, Pembrolizumab for the Treatment of Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.372, issue.21, pp.2018-2046, 2015.
DOI : 10.1056/NEJMoa1501824

Y. Wang, C. Sung, and C. Dartois, Elucidation of Relationship Between Tumor Size and Survival in Non-Small-Cell Lung Cancer Patients Can Aid Early Decision Making in Clinical Drug Development, Clinical Pharmacology & Therapeutics, vol.24, issue.2, pp.167-74, 2009.
DOI : 10.1093/jnci/92.3.205

L. Claret, R. Bruno, and J. Lu, Exploratory Modeling and Simulation to Support Development of Motesanib in Asian Patients With Non???Small Cell Lung Cancer Based on MONET1 Study Results, Clinical Pharmacology & Therapeutics, vol.118, issue.4, pp.446-51, 2014.
DOI : 10.1038/clpt.2012.78

B. Ribba, N. Holford, and P. Magni, A Review of Mixed-Effects Models of Tumor Growth and Effects of Anticancer Drug Treatment Used in Population Analysis, CPT Pharmacometrics Syst. Pharmacol., vol.59, issue.5, p.113, 2014.
DOI : 10.1016/j.jtbi.2012.12.013